Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 794

1.

Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis.

Brydak L, Roiz J, Faivre P, Reygrobellet C.

Clin Drug Investig. 2012 Feb 1;32(2):73-85. doi: 10.2165/11594030-000000000-00000.

PMID:
22201294
2.

The cost-effectiveness of a universal influenza vaccination program for adults aged 50-64 years in Australia.

Newall AT, Scuffham PA, Kelly H, Harsley S, Macintyre CR.

Vaccine. 2008 Apr 16;26(17):2142-53. doi: 10.1016/j.vaccine.2008.01.050. Epub 2008 Feb 20.

PMID:
18343537
3.

Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States.

Clements KM, Chancellor J, Nichol K, DeLong K, Thompson D.

Value Health. 2011 Sep-Oct;14(6):800-11. doi: 10.1016/j.jval.2011.03.005.

4.

Could a federal program to promote influenza vaccination among elders be cost-effective?

Patel MS, Davis MM.

Prev Med. 2006 Mar;42(3):240-6. Epub 2006 Feb 15.

PMID:
16480761
5.
6.

The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.

Aballéa S, Chancellor J, Martin M, Wutzler P, Carrat F, Gasparini R, Toniolo-Neto J, Drummond M, Weinstein M.

Value Health. 2007 Mar-Apr;10(2):98-116.

7.

Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.

Ryan J, Zoellner Y, Gradl B, Palache B, Medema J.

Vaccine. 2006 Nov 17;24(47-48):6812-22. Epub 2006 Aug 4.

PMID:
17034909
8.

Cost-effectiveness of influenza vaccination in working-age cancer patients.

Avritscher EB, Cooksley CD, Geraci JM, Bekele BN, Cantor SB, Rolston KV, Elting LS.

Cancer. 2007 Jun 1;109(11):2357-64.

9.

Cost-effectiveness study on influenza prevention in Hong Kong.

Fitzner KA, Shortridge KF, McGhee SM, Hedley AJ.

Health Policy. 2001 Jun;56(3):215-34.

PMID:
11399347
10.

Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities.

You JH, Wong WC, Ip M, Lee NL, Ho SC.

J Epidemiol Community Health. 2009 Nov;63(11):906-11. doi: 10.1136/jech.2008.081885. Epub 2009 Jul 15.

PMID:
19608558
11.

Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland.

Grzesiowski P, Aguiar-Ibáñez R, Kobryń A, Durand L, Puig PE.

Hum Vaccin Immunother. 2012 Oct;8(10):1382-94. doi: 10.4161/hv.21571. Epub 2012 Oct 1.

12.

The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.

Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.

13.

Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older.

Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ.

Am J Prev Med. 2006 Jul;31(1):72-9. Review.

PMID:
16777545
14.

Estimating the cost-effectiveness of a national program to eliminate disparities in influenza vaccination rates among elderly minority groups.

Michaelidis CI, Zimmerman RK, Nowalk MP, Smith KJ.

Vaccine. 2011 Apr 27;29(19):3525-30. doi: 10.1016/j.vaccine.2011.02.098. Epub 2011 Mar 12.

PMID:
21406266
15.

Should programmes for community-level meningococcal vaccination be considered in Australia? An economic evaluation.

Skull SA, Butler JR, Robinson P, Carnie J.

Int J Epidemiol. 2001 Jun;30(3):571-8; discussion 578-9.

PMID:
11416085
16.
17.

The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain.

Aballéa S, De Juanes JR, Barbieri M, Martin M, Chancellor J, Oyagüez I, Verwee B, Largeron N.

Vaccine. 2007 Sep 28;25(39-40):6900-10. Epub 2007 Aug 6.

PMID:
17764790
18.

Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.

Luce BR, Nichol KL, Belshe RB, Frick KD, Li SX, Boscoe A, Rousculp MD, Mahadevia PJ.

Vaccine. 2008 Jun 2;26(23):2841-8. doi: 10.1016/j.vaccine.2008.03.046. Epub 2008 May 6.

PMID:
18462851
19.

[A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].

Vitale F, Barbieri M, Dirodi B, Vitali Rosati G, Franco E.

Ann Ig. 2013 Jan-Feb;25(1):43-56. doi: 10.7416/ai.2013.1905. Italian.

PMID:
23435779
20.

Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.

Meier G, Gregg M, Poulsen Nautrup B.

J Med Econ. 2015;18(9):746-61. doi: 10.3111/13696998.2015.1044456. Epub 2015 Jun 8.

PMID:
25903831

Supplemental Content

Support Center